Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma

Investigative Radiology

Volumn 48, Issue 6, 2013, Pages 413-421

  Thompson, Scott M ^a   Callstrom, Matthew R ^b   Knudsen, Bruce E ^b   Anderson, Jill L ^b   Sutor, Shari L ^c   Butters, Kim A ^b   Kuo, Chaincy ^c   Grande, Joseph P ^d   Roberts, Lewis R ^c   Woodrum, David A ^b  

^a Mayo Clinic College of Medicine   (United States)

^b Department of Radiology ^*  (United States)

^c MAYO CLINIC   (United States)

^d PERKINELMER INC   (United States)

Author keywords

animal model; bioluminescence imaging; hepatocellular carcinoma; laser ablation; magnetic resonance imaging

Indexed keywords

LUCIFERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE IMAGING; DIMENSIONAL DIFFUSE LUMINESCENCE TOMOGRAPHY; HISTOPATHOLOGY; IMAGING SYSTEM; INTERMETHOD COMPARISON; LASER SURGERY; LIVER CELL CARCINOMA; MALE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; RAT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84877578674     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31827a4a3f     Document Type: Article

References (47)

1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134-1144.
2. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448-458.
3. Yang JD, Kim B, Sanderson SO, et al. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clin Proc. 2012;87:9-16.
4. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349-1354.
5. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24:899-919.
6. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
8. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9: 64-70.
9. Lencioni R, Crocetti L, De Simone P, et al. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. Transpl Int. 2010;23:698-703.
10. Altekruse SF, McGlynn KA, Dickie LA, et al. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology. 2012;55:476-482.
11. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210-1224.
12. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol. 2011;9:32-43.
13. Aravalli RN, Golzarian J, Cressman EN. Animal models of cancer in interventional radiology. Eur Radiol. 2009;19:1049-1053.
14. Aravalli RN, Steer CJ, Sahin MB, et al. Stem cell origins and animal models of hepatocellular carcinoma. Dig Dis Sci. 2010;55:1241-1250.
15. Thompson SM, Callstrom MR, Knudsen B, et al. Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations. J Vasc Interv Radiol. 2012;23: 385-395.
16. Kagadis GC, Loudos G, Katsanos K, et al. In vivo small animal imaging: current status and future prospects. Med Phys. 2010;37:6421-6442.
17. O'Neill K, Lyons SK, Gallagher WM, et al. Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol. 2010;220:317-327.
18. Klerk CP, Overmeer RM, Niers TM, et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques. 2007;43:7-13
19. Kuo C, Coquoz O, Troy TL, et al. Three-dimensional reconstruction of in vivo bioluminescent sources based on multispectral imaging. J Biomed Opt. 2007; 12:024007.
20. Tuli R, Surmak A, Reyes J, et al. Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts. Transl Oncol. 2012;5:77-84.
21. Sun H, Pisle S, Gardner ER, et al. Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models. Cancer Biol Ther. 2010;10:38-43.
22. Inoue Y, Kiryu S, Izawa K, et al. Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging. Eur J Nucl Med Mol Imaging. 2009;36:771-779.
23. Inoue Y, Kiryu S, Watanabe M, et al. Timing of imaging after D-Luciferin injection affects the longitudinal assessment of tumor growth using in vivo bioluminescence imaging. Int J Biomed Imaging. 2010;2010:471408.
24. Caliper-LifeSciences. IVIS 200 Series. Available at: http://www. caliperls.com/products/preclinical-imaging/ivis-imaging-system-200-series.htm. Accessed January 9, 2012.
25. Diaz Encarnacion MM, Griffin MD, Slezak JM, et al. Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant. 2004;4:248-256.
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
27. Guo Y, Zhang Y, Klein R, et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res. 2010;70:1555-1563.
28. Yang W, Ahmed M, Elian M, et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology. 2010;257:685-696.
29. Solazzo SA, Ahmed M, Schor-Bardach R, et al. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology. 2010;255:62-74.
30. Lee EW, Chen C, Prieto VE, et al. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology. 2010;255: 426-433.
31. Cho YK, Kim Y, Rhim H. Pitfalls in the radiological and pathological correlation of tumour response rates of hepatocellular carcinoma following radiofrequency ablation. J Clin Pathol. 2009;62:1071-1073.
32. Bradbury MS, Hambardzumyan D, Zanzonico PB, et al. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med. 2008;49:422-429.
33. Newell P, Villanueva A, Friedman SL, et al. Experimental models of hepatocellular carcinoma. J Hepatol. 2008;48:858-879.
34. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21:35-43.
35. Hsu AR, Cai W, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med. 2007;48:445-454.
36. Inoue Y, Masutani Y, Kiryu S, et al. Integrated imaging approach to tumor model mice using bioluminescence imaging and magnetic resonance imaging. Mol Imaging. 2010;9:163-172.
37. Song HT, Jordan EK, Lewis BK, et al. Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med. 2009;7:88.
38. Inoue Y, Izawa K, Tojo A, et al. Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. Exp Hematol. 2007;35:407-415.
39. Koo V, Hamilton PW, Williamson K. Non-invasive in vivo imaging in small animal research. Cell Oncol. 2006;28:127-139.
40. Joshi CN, Jain SK, Murthy PS. An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Brain Res Protoc. 2004;13:11-17.
41. Guo Y, Klein R, Omary RA, et al. Highly malignant intra-hepatic metastatic hepatocellular carcinoma in rats. Am J Transl Res. 2010;3:114-120.
42. Thompson SM, Callstrom MR, Knudsen B, et al. AS30D model of hepatocellular carcinoma: tumorigenicity and preliminary characterization by imaging, histopathology, and immunohistochemistry. Cardiovasc Intervent Radiol. 2012. [Epub ahead of print].
43. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-773.
44. McWilliams JP, Yamamoto S, Raman SS, et al. Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol. 2010;21: S204YS213.
45. Poff JA, Allen CT, Traughber B, et al. Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology. 2008;248:485-491.
46. Kagawa T, Koizumi J, Kojima S, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010;116:3638-3644.
47. Kadivar F, Soulen MC. Enhancing ablation: synergies with regional and systemic therapies. J Vasc Interv Radiol. 2010;21:S251YS256.